Actively Recruiting
A Study of HS-20110 in Participants With Advanced Solid Tumors
Led by Hansoh BioMedical R&D Company · Updated on 2026-04-20
475
Participants Needed
8
Research Sites
135 weeks
Total Duration
On this page
Sponsors
H
Hansoh BioMedical R&D Company
Lead Sponsor
H
Hoffmann-La Roche
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
CONDITIONS
Official Title
A Study of HS-20110 in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males or females aged 18 years or older
- Participants with pathologically confirmed advanced solid tumors
- Participants have at least one measurable target lesion outside the central nervous system according to RECIST 1.1
You will not qualify if you...
- Prior or current treatment with CDH17-targeted therapies such as small molecule drugs, monoclonal or bispecific antibodies, antibody-drug conjugates, or CAR T cells
- Anti-tumor drugs within 14 days or other investigational or macromolecular anti-tumor drugs within 28 days before first study dose
- Local radiotherapy within 2 weeks or extensive radiotherapy involving more than 30% of bone marrow within 4 weeks before first dose
- Major surgery within 4 weeks before first dose
- Treatment with moderate to strong CYP3A4 or CYP2D6 inhibitors or inducers, P-gp or BCRP modulators, or narrow therapeutic range substrates within 7 days before first dose, or planned use during the study
- Use of drugs known to prolong QT interval or cause torsade de pointes, or planned use during the study
- Live or live-attenuated vaccine within 28 weeks before first dose
- Residual toxicity of Grade 2 or higher from prior therapies (except alopecia and neurotoxicity)
- Inadequate bone marrow, liver, or kidney function
- History of severe allergy, anaphylactic shock, or severe infusion reactions
- Allergy to any component of HS-20110
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
BRCR Medical Center INC
Tamarac, Florida, United States, 33321
Actively Recruiting
2
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States, 46804
Actively Recruiting
3
Carolina BioOncology Institute
Huntersville, North Carolina, United States, 28078
Actively Recruiting
4
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
5
NEXT Dallas
Irving, Texas, United States, 75039
Actively Recruiting
6
NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
7
NEXT Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
8
SUN YAT-SEN University Cancer Center
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
H
Hongyan Wang
CONTACT
A
Amanda Guo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here